Clinical Trial Results: Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial results on nilotinib in mild to moderate Alzheimer's disease; evaluates safety, biomarkers, and clinical outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Georgetown University | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-07-23